At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
DA-9805 45mg +2 moredrug
Likely dose
DA-9805 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating DA-9805 45mg, DA-9805 90mg, and 1 other intervention for Parkinson's Disease. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartFeb 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedJun 16, 2017
Enrollment StartFeb 6, 2018
Primary CompletionApr 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.0 years ago
Interventions
DA-9805 45mgdrug
DA-9805 15mg tid
DA-9805 90mgdrug
DA-9805 30mg tid
Placeboother
Placebo, tid